Drug Trial Radar · NCT05227820
Insulin-Sensitizing Anti-Inflammatory Small Molecule for Investigative Treatment of Dementia
Last checked: Nov 19, 2026Latest source record: Jul 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
23
Actual
Start
Jan 19, 2022
Primary completion
Jul 20, 2022
Study completion Aug 20, 2022
Sponsor
- Lead sponsor
- Neurological Associates of West Los AngelesAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- BioVie Inc.
- First posted
- Feb 7, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 55 years, up to 89 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study seeks to measure changes in cognition through verbal and visual test procedures and changes in biomarkers of Alzheimer's disease and inflammatory and metabolic parameters that can be measure in the central nervous system (CNS) with advanced neuroimaging techniques in patients treated with NE3107 (17a-ethynyl-androst-5-3b,7b,17b-triol).
Conditions
- Alzheimer Disease
Interventions
NE3107Drug
Participants will take 20mg twice daily (BID) approximately 12 hours apart. The dose will be stable the duration of the study intervention (3 months)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in fMRITime frame: 3 Months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Neurological Associates - The Interventional Group
Santa Monica, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.